Autoimmune encephalitis: Epidemiology, pathophysiology and clinical spectrum (part 2)
DOI:
https://doi.org/10.7196/SAMJ.2023.v113i4.875Keywords:
autoimmune, encephalitisAbstract
Autoimmune encephalitis (AE) represents a growing number of severe autoimmune-inflammatory diseases affecting both the white and grey matter of the brain. In part 1 of this series we focused on the epidemiology, pathophysiology and clinical presentation of this condition, with two illustrative cases. In this part, we will introduce the clinical criteria for AE, particularly for the diagnosis of anti-N-methyl-D-aspartate (NMDA) receptor encephalitis, which were developed to facilitate immune treatment in suspected cases before antibody results are available. We subsequently discuss the work up, differential diagnosis and treatment options for patients with this disease.
References
Venkatesan A, Tunkel AR, Bloch KC, et al. International Encephalitis Consortium. Case definitions, diagnostic algorithms, and priorities in encephalitis: Consensus statement of the International Encephalitis Consortium. Clin Infect Dis 2013;57(8):1114-1128. https://doi/10.1093/cid/cit458
Graus F, Titulaer MJ, Balu R, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol 2016;15(4):391-404. https://doi.org/10.1016/S1474-4422(15)00401-9.
Titulaer MJ, McCracken L, Gabilondo I, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol. 2013;12(2):157-165. https://doi.org/10.1016/S1474-4422(12)70310-1.
Dalmau J, Graus F. Antibody-mediated encephalitis. N Engl J Med 2018;378:840-851. https://doi.org/10.1056/NEJMra1708712
Dalmau J, Lancaster E, Martinez-Hernandez E, et al. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol 2011;10(1):63-74. https://doi.org/10.1016/S1474-4422(10)70253-2
Kelley BP, Patel SC, Marin HL, et al. Autoimmune encephalitis: Pathophysiology and imaging review of an overlooked diagnosis. Am J Neuroradiol 2017;38(6):1070-1078. https://doi.org/10.3174/ajnr.A5086
Son DK, Cho SM, Ryu HU, et al. Anti-NMDAR encephalitis with bilateral basal ganglia MRI lesions at a distance of time: A case report. BMC Neurol 2022;22:121. https://doi.org/10.1186/s12883-022-02652-y
Heine J, Prüss H, Bartsch T, et al. Imaging of autoimmune encephalitis – relevance for clinical practice and hippocampal function. Neuroscience 2015;19(309):68-83. https://doi.org/10.1016/j.neuroscience.2015.05.037
Kovac S, Alferink J, Ahmetspahic D, et al. Update Anti-N-Methyl-D-Aspartat-Rezeptor-Enzephalitis [Update on anti-N-methyl-D-aspartate receptor encephalitis]. Nervenarzt 2018;89(1):99-112. https://doi.org/10.1007/s00115-017-0405-0
Veciana M, Becerra JL, Fossas P, et al. EEG extreme delta brush: An ictal pattern in patients with anti-NMDA receptor encephalitis. Epilepsy Behav 2015;49:280-285. https://doi.org/ 10.1016/j.yebeh.2015.04.032.
Schmitt SE, Pargeon K, Frechette ES, et al. Extreme delta brush: A unique EEG pattern in adults with anti-NMDA receptor encephalitis. Neurology 2012;11;79(11):1094-1100. https://doi.org/10.1212/WNL.0b013e3182698cd8
Parwani J, Ortiz JF, Alli A, et al. Understanding seizures and prognosis of the extreme delta brush pattern in anti-N-methyl-D-aspartate (NMDA) receptor encephalitis: A systematic review. Cureus 2021;21;13(9):e18154. https://doi.org/10.7759/cureus.18154
Gaspard N, Foreman BP, Alvarez V, et al. New-onset refractory status epilepticus: Etiology, clinical features, and outcome. Neurology 2015;85(18):1604-1613. https://doi.org/ 10.1212/WNL.0000000000001940
Granerod J, Ambrose HE, Davies NW, et al. Causes of encephalitis and differences in their clinical presentations in England: A multicentre, population-based prospective study. Lancet Infect Dis 2010;10(12):835-844. https://doi.org/10.1016/s1473-3099(10)70222-x
Wang R, Guan HZ, Ren HT, et al. CSF findings in patients with anti-N-methyl-D-aspartate receptor-encephalitis. Seizure 2015;29:137-142. https://doi.org/10.1016/j.seizure.2015.04.005
Irani SR, Bera K, Waters P, et al. N-methyl-D-aspartate antibody encephalitis: Temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes. Brain 2010;133(6):1655-1667. https://doi.org/ 10.1093/brain/awq113
Gresa-Arribas N, Titulaer MJ, Torrents A, et al. Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: A retrospective study. Lancet Neurol 2014;13(2):167-177. https://doi.org/10.1016/S1474-4422(13)70282-5
Prüss H, Finke C, Höltje M, et al. N-methyl-D-aspartate receptor antibodies in herpes simplex encephalitis. Ann Neurol 2012;72(6):902-911. https://doi.org/10.1002/ana.23689
Leypoldt F, Titulaer MJ, Aguilar E, et al. Herpes simplex virus-1 encephalitis can trigger anti-NMDA receptor encephalitis: Case report. Neurology 2013;81(18):1637-1639. https://doi.org/10.1212/WNL.0b013e3182a9f531
Lejuste F, Thomas L, Picard G, et al. Neuroleptic intolerance in patients with anti-NMDAR encephalitis. Neurol Neuroimmunol Neuroinflamm 2016;3(5):e280. https://doi.org/10.1212/NXI.0000000000000280
Abboud H, Probasco JC, Irani S, et al. Autoimmune encephalitis: Proposed best practice recommendations for diagnosis and acute management. J Neurol Neurosurg Psychiatr 2021;92:757-768. https://doi.org/10.1136/jnnp- 2021- 326096
Nepal G, Shing YK, Yadav JK, et al. Efficacy and safety of rituximab in autoimmune encephalitis: A meta-analysis. Acta Neurol Scand 2020;142(5):449-459. https://doi.org/10.1111/ane.13291
Uy CE, Binks S, Irani SR. Autoimmune encephalitis: Clinical spectrum and management. Pract Neurol 2021;21(5):412-423. https://doi.org/10.1136/practneurol-2020-002567
Dinoto A, Ferrari S, Mariotto S. Treatment Options in Refractory Autoimmune Encephalitis. CNS Drugs. 2022;2. https://doi.org/10.1007/s40263-022-00943-z
Broadley J, Seneviratne U, Beech P, et al. Prognosticating autoimmune encephalitis: A systematic review. J Autoimmun 2019;96:24-34. https://doi.org/10.1016/j.jaut.2018.10.014.
Zhong R, Chen Q, Zhang X. Relapses of anti-NMDAR, anti-GABABR and anti-LGI1 encephalitis: A retrospective cohort study. Front Immunol 2022;9(13):918396. https://doi.org/10.3389/fimmu.2022.918396
Liu X, Guo K, Lin J, et al. Long-term seizure outcomes in patients with autoimmune encephalitis: A prospective observational registry study update. Epilepsia 202;63(7):1812-1821. https://doi.org/10.1111/epi.17245
Hébert J, Day GS, Steriade C, et al. Long-term cognitive outcomes in patients with autoimmune encephalitis. Can J Neurol Sci 2018;45(5):540-544. https://doi.org/10.1017/cjn.2018.33
Balu R, McCracken L, Lancaster E. A score that predicts 1-year functional status in patients with anti-NMDA receptor encephalitis. Neurology 2019;92(3):e244-e252. https://doi.org/10.1212/WNL.0000000000006783
Thompson J, Bi M, Murchison AG, et al. Faciobrachial Dystonic Seizures Study Group. The importance of early immunotherapy in patients with faciobrachial dystonic seizures. Brain 2018;141(2):348-356. https://doi.org/10.1093/brain/awx323
Schubert J, Brämer D, Huttner HB, GENERATE and IGNITE network. Management and prognostic markers in patients with autoimmune encephalitis requiring ICU treatment. Neurol Neuroimmunol Neuroinflamm 2018;6(1):e514. https://doi.org/ 10.1212/NXI.0000000000000514
Downloads
Published
Issue
Section
License
Copyright (c) 2023 J Hiesgen, C M Schutte
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Licensing Information
The SAMJ is published under an Attribution-Non Commercial International Creative Commons Attribution (CC-BY-NC 4.0) License. Under this license, authors agree to make articles available to users, without permission or fees, for any lawful, non-commercial purpose. Users may read, copy, or re-use published content as long as the author and original place of publication are properly cited.
Exceptions to this license model is allowed for UKRI and research funded by organisations requiring that research be published open-access without embargo, under a CC-BY licence. As per the journals archiving policy, authors are permitted to self-archive the author-accepted manuscript (AAM) in a repository.
Publishing Rights
Authors grant the Publisher the exclusive right to publish, display, reproduce and/or distribute the Work in print and electronic format and in any medium known or hereafter developed, including for commercial use. The Author also agrees that the Publisher may retain in print or electronic format more than one copy of the Work for the purpose of preservation, security and back-up.
